2002
DOI: 10.1097/00006254-200209000-00016
|View full text |Cite
|
Sign up to set email alerts
|

Risk-Reducing Salpingo-Oophorectomy in Women With a BRCA1 or BRCA2 Mutation

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

12
519
1
17

Year Published

2003
2003
2016
2016

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 370 publications
(549 citation statements)
references
References 0 publications
12
519
1
17
Order By: Relevance
“…It has been shown that BSO in carriers of BRCA1 and BRCA2 mutations reduces the risk of developing malignancy of the coelomic epithelium by up to 96%, although some series have found a slightly lower risk reduction, and it is estimated that BSO reduces the risk of breast carcinoma by approximately 50% in premenopausal BRCA1 and BRCA2 mutation carriers. 36,37 A protective effect of tamoxifen in the 50% range against contralateral breast carcinoma has been observed in both BRCA1 carriers and BRCA2 carriers, although a question remains about the ability of tamoxifen to reduce the risk of hormone receptor-negative tumors that often are associated with BRCA1. 5,38 Thirty-six point six percent of the current cohort consisted of women who had their risk reduced before their initial screen.…”
Section: Discussionmentioning
confidence: 99%
“…It has been shown that BSO in carriers of BRCA1 and BRCA2 mutations reduces the risk of developing malignancy of the coelomic epithelium by up to 96%, although some series have found a slightly lower risk reduction, and it is estimated that BSO reduces the risk of breast carcinoma by approximately 50% in premenopausal BRCA1 and BRCA2 mutation carriers. 36,37 A protective effect of tamoxifen in the 50% range against contralateral breast carcinoma has been observed in both BRCA1 carriers and BRCA2 carriers, although a question remains about the ability of tamoxifen to reduce the risk of hormone receptor-negative tumors that often are associated with BRCA1. 5,38 Thirty-six point six percent of the current cohort consisted of women who had their risk reduced before their initial screen.…”
Section: Discussionmentioning
confidence: 99%
“…[101][102][103] RRBSO is now considered the optimal risk-management strategy for this population of high-risk women. [19][20][21][22] Choosing RRBSO appears to be related to older age, perceived cancer risk, and perceived benefit of surgery. [99][100][101][104][105][106] In a 2012 long-term outcome study, Schwartz et al observed that >80% of BRCA1/BRCA2 carriers had undergone RRM, or RRBSO, or both at approximately 5 years after testing.…”
Section: Hbocmentioning
confidence: 99%
“…In addition, for BRCA1/BRCA2 carriers, risk-reducing bilateral salpingo-oophorectomy (RRBSO) is recommended after the completion of childbearing to decrease the risk of both ovarian cancer and breast cancer, and they also are offered the option of risk-reducing bilateral mastectomy (RRM). [19][20][21][22] Individuals who have HNPCC-related mutations have a similarly high lifetime risk of developing colon cancer of approximately 25% to 75% and an approximately 30% to 70% risk of developing endometrial cancer. 23 Individuals with Lynch syndrome also are predisposed to other cancers, such as urothelial cancers, small bowel cancer in men, and breast cancer in women.…”
Section: Introductionmentioning
confidence: 99%
“…Several studies have reported that the incidence of breast cancer declines in women with BRCA1 or BRCA2 mutations following an oopohorectomy Kauff et al, 2002;Eisen et al, 2005). In the largest of these, Eisen et al (2005) performed a casecontrol study on 1439 BRCA mutation carriers with breast cancer, and 1866 matched controls without breast cancer.…”
Section: Oophorectomymentioning
confidence: 99%